Company Encyclopedia
View More
name
SIPAI HEALTH
00314.HK
Sipai Health Technology Co., Ltd. operates as a medical technology and health management company in the People’s Republic of China. The company operates through three segments: Specialty Pharmacy Business, Physician Research Assistance Business, and Health Insurance Services Business. The Specialty Pharmacy Business segment provides specialty pharmacies and value-added professional pharmacist services; focuses on innovative medicines for the treatment of oncology; pharmaceutical supply chain network for health insurance services; and other critical illnesses.
310.87 B
00314.HKMarket value -Rank by Market Cap -/-

Financial Score

11/12/2025 Update
D
Drug RetailIndustry
Industry Ranking7/7
Industry medianB
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-25.48%E
    • Profit Margin-9.27%D
    • Gross Margin14.39%D
  • Growth ScoreE
    • Revenue YoY-26.03%E
    • Net Profit YoY-31.60%D
    • Total Assets YoY-36.01%E
    • Net Assets YoY-35.57%E
  • Cash ScoreE
    • Cash Flow Margin-1078.90%E
    • OCF YoY-26.03%E
  • Operating ScoreA
    • Turnover1.44A
  • Debt ScoreC
    • Gearing Ratio47.81%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sipai Health Technology Files HKEX Disclosure on Repurchase of 263,200 Shares for HKD 651,924

    Sipai Health Technology Co. Ltd. has disclosed to the Hong Kong Stock Exchange that it repurchased 263,200 shares for a total of HKD 651,924. The shares will be held as treasury shares.

    Reuters·
    HK
    00314
    +0.42%
    Reuters·
    HK
    00314
    +0.42%

    Sipai Health Technology Updates on Share Schemes

    Sipai Health Technology Co., Ltd. (HK:0314) has issued a supplemental announcement regarding its share schemes, including the 2017 Plan and the RSU Scheme. The announcement reveals a decrease in outstanding options and shares, with the 2017 Plan having about three years left and the RSU Scheme terminated early. The latest analyst rating for HK:0314 is a Sell, with a price target of HK$4.50. The company's current market cap is HK$2.07B, and the average trading volume is 5,045,472 shares.

    Tip Ranks·
    HK
    00314
    +0.42%
    Tip Ranks·
    HK
    00314
    +0.42%

    Sipai Health Technology Co. Ltd. Narrows Normalized Net Loss by 59.6% to RMB 12.0 Million in First Half of 2025; Gross Margin Rises to 14.4%

    Sipai Health Technology Co. Ltd. reported a normalized net loss of RMB 12.0 million for the first half of 2025, a 59.6% improvement from RMB 29.7 million in the same period of 2024. The adjusted loss was RMB 24.8 million, down from RMB 28.8 million. The company noted a gross margin increase to 14.4% and highlighted ongoing strategic shifts to align with industry trends and government policy support for the healthcare sector.

    Reuters·
    HK
    00314
    +0.42%
    Reuters·
    HK
    00314
    +0.42%

    CITIC Securities: Maintains "Buy" rating on SIPAI HEALTH with a target price of HKD 6.5

    CITIC Securities released a research report stating that it is optimistic about the development trend of the commercial health insurance industry and the core competitive advantage of SIPAI HEALTH's "medical, pharmaceutical, and insurance" ecological closed loop, with expectations for subsequent profit improvement. Based on the company's strategic optimization and restructuring of the specialty pharmacy business and the benefit insurance business in the first half of 2025, the revenue forecasts for 2025/26/27 have been adjusted to RMB 2.1 billion / 1.94 billion / 2.07 billion (originally forecasted as RMB 4.92 billion / 5.26 billion / 5.57 billion); the net profit forecasts have been adjusted to a loss of RMB 99 million / a loss of RMB 29 million / a profit of RMB 32 million (originally forecasted as a loss of RMB 107 million / a loss of RMB 35 million / a profit of RMB 32 million). Under the absolute valuation method, the target price for the company in 2025 is HKD 6.5, corresponding to RMB 6.0, maintaining a "buy" rating

    Zhitong·
    HK
    00314
    +0.42%
    Zhitong·
    HK
    00314
    +0.42%

    Understanding the Market | EASOU TECH removed from the Hong Kong Stock Connect list, falling over 30%, CONCORD HC GP down over 25%

    After being removed from the Hong Kong Stock Connect list, multiple stocks saw significant declines in early trading. As of the time of publication, EASOU TECH fell by 31.53% to HKD 3.17; CONCORD HC GP dropped by 25.32% to HKD 3.54; CITYCHAMP decreased by 22.71% to HKD 0.228; SIPAI HEALTH declined by 13.6% to HKD 4.7. In terms of news, the Shanghai Stock Exchange and the Shenzhen Stock Exchange respectively announced that due to the adjustment of constituent stocks in the Hang Seng Composite Large Cap Index, Mid Cap Index, and Small Cap Index, the list of eligible securities for the Hong Kong Stock Connect has been adjusted and will take effect from September 8. Among them, 20 stocks, including EASOU TECH, CONCORD HC GP, CITYCHAMP, and SIPAI HEALTH, have been removed

    Zhitong·
    HK
    00314
    +0.42%
    HK
    02550
    +1.95%
    HK
    02453
    -1.60%
    Zhitong·
    HK
    00314
    +0.42%
    HK
    02550
    +1.95%
    HK
    02453
    -1.60%
    © 2025 Longbridge｜Disclaimer